An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator- Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)

PI: Dr. Giuseppe Lo Russo 

This trial is testing pembrolizumab (pembro) with or without sacituzumab govitecan (SG) in adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body. 

Pembrolizumab is an antibody that binds immune cells and helps the immune (protective) response against the tumour. Sacituzumab govitecan is an antibody-drug conjugate (ADC), which, once internalised, releases the drug that induces cell cycle arrest and tumour cell death. 

The drug it receives will depend on which group it is placed in.  

This trial comprises 2 groups: 

• Group 1: will receive pembrolizumab with sacituzumab govitecan (SG). 
• Group 2: will receive pembrolizumab.